Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Red blood cell abnormality01.07.02.0060.001030%Not Available
Blood disorder01.05.01.004--Not Available
Immunodeficiency10.03.02.0020.000303%Not Available
Disease recurrence08.01.03.0500.000455%Not Available
Drug intolerance08.06.01.0130.037582%Not Available
Pulmonary toxicity12.03.01.013; 22.01.02.0070.001061%Not Available
Food intolerance14.02.01.005--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Immunosuppression10.03.02.001--Not Available
Non-cardiac chest pain22.12.02.009; 08.01.08.006--
Heparin-induced thrombocytopenia24.01.01.020; 10.02.01.007; 01.08.01.0040.000303%Not Available
Haemorrhagic diathesis24.07.01.020; 01.01.03.0030.000303%Not Available
Neutropenic colitis01.02.03.010; 07.08.01.0140.000909%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.010--Not Available
Dactylitis15.03.03.009--Not Available
Bone marrow failure01.03.03.0050.000758%
Cytopenia01.03.03.0120.000758%Not Available
Acute interstitial pneumonitis22.01.02.016--Not Available
Treatment failure08.06.01.0170.011881%Not Available
Liver injury12.01.17.012; 09.01.07.0220.001061%Not Available
Organising pneumonia22.01.02.0080.000455%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.000303%Not Available
Focal segmental glomerulosclerosis20.05.01.0030.000303%Not Available
Hypertransaminasaemia09.01.02.0050.000758%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.002091%
Spinal column injury15.02.04.014; 12.01.09.006--Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.000303%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.001424%Not Available
Granulomatosis with polyangiitis22.01.01.015; 20.05.01.013; 10.02.02.018; 24.12.04.0110.000455%Not Available
The 13th Page    First    Pre   13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene